NASDAQ
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast ca...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts across its Precision Oncology portfolio at the 2025 San Antonio Breast Cancer Symposium (SABCS...
MONSEY, N.Y., Nov. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Exact Sciences Corporation (Nasdaq: EXAS) (“Exact Sciences”) to Abbott Laboratories for $105.00 per share in cas...
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact Sciences Corporation (NasdaqCM: EXAS) to Abbott L...
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Sec...
BALA CYNWYD, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Exact Sciences Corporation (“Exact Sciences” or the “Company”) (Nasdaq – EXAS) for...
MILWAUKEE , Nov. 20, 2025 /PRNewswire/ -- The Ademi Firm is investigating Exact Sciences (NASDAQ: EXAS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Abbott. Click here to learn how to ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Exact Sciences Corporation (NASDAQ: EXAS) to Abbott for $105.00 per common share in cash is fair to Exact Sciences shareholders. Halper Sad...
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments Acquisition will uniquely position Abbot...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR...
No price data available for this timeframe.